San Diego, California — August 14, 2025 — Leads & Copy — Thiogenesis Therapeutics Corp. (TSXV: TTI) announced it has received final acceptance from the TSX Venture Exchange for its oversubscribed non-brokered private placement of 5,529,066 common shares for gross proceeds of C$4,146,800 at C$0.75 per share.
The company paid C$266,406 in finder’s fees and issued 353,208 non-transferable finder’s options in connection with the offering. All securities issued are subject to a 4-month plus one day hold period ending December 1, 2025.
Net proceeds will be used for the company’s MELAS clinical trial expenses, the creation and purchase of additional TTI-0102 for future clinical trials, and general working capital. Thiogenesis is a clinical-stage biopharmaceutical company developing sulfur-containing prodrugs.
Brook Riggins, Director and CFO, can be reached at info@thiogenesis.com or (888) 223-9165.
Source: Thiogenesis Therapeutics Corp.
